
Market Analysis in a Feasibility Study
Market analysis is the part of a feasibility study that decides where to place a practice and whether the numbers hold up. Here is why it matters.
Few specialties lose revenue in as many places as Rheumatology. When you buy and bill biologics, you purchase expensive medication upfront and depend on precise coding to recover the cost. The drug has to be reported with the correct J-code and the right number of units converted from the NDC, waste has to be documented with the proper modifiers, and the prior authorization has to be approved before the infusion. Miss anyone, and a clean claim becomes a denial. Payor pressure to shift drugs to white bagging or brown bagging adds another layer that can quietly erode your margin. Not to mention, the shrinking reimbursement is costing rheumatologists millions in profitability.
CHCBC helps you find and fix these breakdowns. Our consultants run a full revenue cycle assessment that shows where claims are stalled, why denials happen, and how much revenue you can still recover. From there, we look at the workflows behind the numbers, from infusion coding and unit calculation to prior authorization and charge capture, and prioritize the fixes that return the most revenue first.
We're always available to answer your questions.
Client based strategies designed specifically for your business.
Over 30 years of experience as a Certified Healthcare Consultant.
We provide fresh ideas and successful results to your business.
Growth in Rheumatology adds complexity fast. More infusions mean more prior authorizations, more drug inventory to manage, and more pressure on the same chairs and the same nursing staff. Your current payor contracts may not reflect the rising cost of the biologics you administer. Without the right structure, expansion erodes margins instead of strengthening them.
We help Rheumatology practices grow on a solid foundation. CHCBC evaluates your infusion capacity, payor mix, and fee schedules, then negotiates payor contracts so your infusion administration and drug reimbursement are fair. From productivity benchmarking to startup planning for a new infusion suite, our consultants give you the structure to expand with confidence.
CHCBC works exclusively with healthcare practices, and we understand the financial, operational, and compliance pressures that define rheumatology. We bring practical, data-driven guidance that translates directly into stronger cash flow and lower risk.
• Specialty focus: deep experience with buy-and-bill economics, infusion and biologic coding, and the prior authorization workflows that gate high-cost drugs.
• Revenue protection: we reduce denials and underpayments by fixing root causes, not just reworking claims after the fact. We also work with you and the payors on reimbursement and contracting provisions strategies to combat the losses seen in the last couple of years
• Compliance support: we help you build documentation and audit-ready processes for drug purchasing, infusion administration, and billing.
• Full-practice view: from the front desk to payor contracts, we align operations and finances around measurable results.
Identifies denials, unit and modifier errors, and accounts receivable issues across infusions, injectables, and office visits.
Renegotiates terms for infusion administration and biologic drug reimbursement so payment reflects the cost of care.
Aligns your fee schedule with drug acquisition cost and market reimbursement for an infusion-heavy Rheumatology practice.
Builds fair, compliant compensation models that balance clinic and infusion productivity with fair market value, know what to offer a new partner, validate current production.
Gives patients clear cost estimates before infusions and treatment, reducing surprise balances and accounts receivable
Streamlines credentialing and payor enrollment for physicians and advanced practice clinicians so new providers can bill without delay.

Market analysis is the part of a feasibility study that decides where to place a practice and whether the numbers hold up. Here is why it matters.

The 2026 Revenue Cycle Reality: Payer Complexity, Patient Balances, and Systemic Risk Revenue cycle performance is under more pressure in

Why Dermatology Revenue Cycle Management Requires a Specialized Approach Dermatology practices operate within a highly detailed billing and reimbursement structure.
Fill out the form below to download our How Will 2026 CMS Reimbursement Changes Affect You PDF
"*" indicates required fields